Bioterrorism
AVI BioPharma Receives DoD Contracts for Bioterrorism Response Therapies
Published in Gene Therapy Weekly, May 24th, 2007
AVI BioPharma, Inc. (Nasdaq: AVII), announced the receipt of three signed contracts valued at $7.1 million from the Department of Defense for the development of therapeutic drugs against potential bioterrorism agents, using AVI's NEUGENE(R) technology. The contracts, including $2.66 million to develop antisense agents to treat Ebola virus infections, $2.66 million to treat Marburg virus infections, and $1.78 million to develop countermeasures for exposure to Bacillus anthracis (anthrax) and ricin toxin, were part of a previously announced budget allocation.
"We are extremely pleased to receive these contracts after the extensive due diligence and peer review process...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2007-05-24)
More Articles from Gene Therapy Weekly
- Breast Cancer
Molecules with Potential to Treat Breast Cancer Found - Gene Therapy
Dealing Deadly Cancers a Knockout Punch - Ovarian Cancer
Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer - Cancer Vaccines
Phase I Trial for ImmunoCellular Therapeutics Brain Tumor Vaccine Commences - Gene Therapy
Altus Pharmaceuticals Inititates Phase III Clinical Trials of ALTU-135 for Cystic Fibrosis Patients with Pancreatic Insufficiency - Gene Therapy
CEO of World's First Profitable Regenerative Medicine Company, ORGANOGENESIS, Details Path to Profitability for the Regenerative Medicine Field - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
